title: Lineage-specific biomarkers predict response to FGFR inhibition.
abstract: In this issue of Cancer Discovery, Guagnano and colleagues use a large and diverse annotated collection of cancer cell lines, the Cancer Cell Line Encyclopedia, to correlate whole-genome expression and genomic alteration datasets with cell line sensitivity data to the novel pan-fibroblast growth factor receptor (FGFR) inhibitor NVP-BGJ398. Their findings underscore not only the preclinical use of such cell line panels in identifying predictive biomarkers, but also the emergence of the FGFRs as valid therapeutic targets, across an increasingly broad range of malignancies.
authors.affiliation: Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.
authors.forename: David C
authors.initials: DC
authors.lastname: Loch
authors.forename: Pamela M
authors.initials: PM
authors.lastname: Pollock
mesh_terms: D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D010671:Phenylurea Compounds / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics*
chemical_list: D010671:Phenylurea Compounds; D011743:Pyrimidines; D017468:Receptors, Fibroblast Growth Factor; C568950:infigratinib